Nyxoah (NYXH) CMD 2026 summary

Strategic direction and market positioning

• Focused on U.S. commercial execution, targeting top 400 high-volume accounts to efficiently capture market share and drive adoption of Genio therapy for obstructive sleep apnea.

• Differentiation centers on bilateral hypoglossal nerve stimulation, single-incision design, and strong appeal among patients with aesthetic, MRI, and lifestyle concerns.

• GLP-1 therapies are viewed as a diagnostic catalyst, increasing patient awareness and expanding the eligible treatment pool for Genio.

• Company is leveraging wearables and cloud-based telemonitoring to enhance patient engagement and compliance.

• Strategic collaboration with physician societies and focus on innovation in device design and patient pathway management.

Financial guidance and path to profitability

• Achieved over 20% quarter-over-quarter global revenue growth in Q2, with $9 million in revenue and a fivefold year-over-year increase.

• Break-even targeted at €150 million annualized revenue, representing about 15% U.S. HGNS market share, supported by historical share gains in Germany and early U.S. accounts.

• Gross margin expected to rise to 80%+ by 2027 through Genio 2.1 device launch and volume-based manufacturing efficiencies.

• Operating expenses managed tightly, with redeployment of resources to U.S. commercial expansion and a recent successful capital raise to fund growth to profitability.

• Guidance for 2026 revenue remains €36–40 million, with strong patient pipeline and backlog supporting confidence in future growth.

Reimbursement and regulatory landscape

• Coding and reimbursement for Genio are stable, with CMS C codes in place and commercial payers providing favorable rates; no risk of losing reimbursement regardless of competitor code changes.

• Collaboration with AAO-HNS and other societies is prioritized for future CPT code submissions, aiming for a comprehensive approach rather than company-specific codes.

• Any new CPT codes for competitors will not orphan Genio or impact its reimbursement; current codes remain valid and granular.

• Physician and facility reimbursement parity is maintained, and coding changes are not expected to disrupt coverage or payment.

• Pathways for future code submissions are prepared, with strategic flexibility to act as market and regulatory conditions evolve.